When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal

Journal of Hypertension

Volumn 27, Issue 5, 2009, Pages 923-934

  Zanchetti, Alberto ^a   Grassi, Guido ^a,b   Mancia, Giuseppe ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive therapy; Target blood pressure; Treatment initiation; Trials

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; DIAMICRON MR; ENALAPRIL; GLICLAZIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 67649651744     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832aa6b5     Document Type: Review

References (61)

1. World Health Organization/International Society of Hypertension. 2003 World Health Organization/WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
2. Guideline Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
4. Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29(Suppl):1-106.
5. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105-1187.
6. Burlando G, Sanchez R, Ramos F, Mogensen C, Zanchetti A, on behalf of the Latin American Experts Group. Latin America consensus on diabetes mellitus and hypertension. J Hypertens 2004; 22:2229-2241.
7. Graham I, Atar D, Borch-Jonsen K, Boysen G, Burrell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28:2375-2414.
8. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-1464.
9. Hypertension, Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. J Am Med Assoc 1979; 242:2562-2571.
10. Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1:1261-1267.
11. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980; 69:725-732.
12. Hypertension, Detection and Follow-up Program Cooperative Group. Five-yearfindings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247:633-638.
13. Hypertension, Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-year findings of the Hypertension Detection and Follow-up Program. Hypertension 1984; 6 (Suppl I): I198-I206.
14. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-1354.
15. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291:97-104.
16. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293:1145-1151.
17. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991; 265:3255-3264.
18. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
19. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304:405-412.
20. PATS Collaborative Group. Poststroke antihypertensive treatment study. Chin Med J 1995; 108:710-717.
21. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J Am Med Assoc 1996; 276:1886-1892.
22. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
23. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS38. Br Med J 1998; 317:703-713.
25. Liu L, Wang JL, Gong L, Liu G, Staessen JA, for the Syst-China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
26. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al., for the Systolic Hypertension in Europe Trial Investigators. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684.
27. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl. 2):B54-B64.
28. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342:145-153.
29. The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in MICROHOPE substudy. Lancet 2000; 355:253-259.
30. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini CBJ, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510.
31. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
33. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
34. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61:1086-1097.
35. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al., HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients in the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21:797-804.
36. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21:875-886.
37. The EUropean trial On Reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
38. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al., Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1703.
39. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser M-G, Colman SA, et al., on behalf of the PROGRESS Collaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS trial. Blood Pressure 2004; 13:7-13.
40. Poole-Wilson PA, Lubsen J, Kirwan B-A, van Dalen FJ, Wagener G, Danchin N, et al., on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
41. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al., CAMELOT investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2003; 292:221 7-2225.
42. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary disease. N Engl J Med 2004; 351:2058-2068.
43. Lubsen J, Wagener G, Kirwan B-A, de Brouwer S, Poole-Wilson PA, on behalf of ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:641-648.
44. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, for the FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172.
45. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. for the PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201-1208.
46. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
47. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrescu D, et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
48. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al., for the PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
49. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting-enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:11 74-1183.
50. JATOS Study Group. Principle results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (SATOS). Hypertens Res 2008; 31:2115-2124.
51. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 2008; 336:1121-1123.
52. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-2110.
53. Zanchetti A, Mancia G. The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations. J Hypertens 2009; 27:1-2.
54. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009; 27 (in press).
55. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged difference in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
56. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 20023; 360:1903-1913.
57. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens 2005; 23:1113-1120.
58. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L, et al. Impact of achieved blood on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170-2179.
59. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16:3027-3037.
60. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
61. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11-19.